Hsbc Holdings PLC Makes New Investment in CG Oncology, Inc. $CGON

Posted by Francis Steltz on Aug 29th, 2026

Hsbc Holdings PLC bought a new stake in shares of CG Oncology, Inc. (NASDAQ:CGON – Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 175,765 shares of the company’s stock, valued at approximately $12,488,000.

Other large investors have also modified their holdings of the company. Fiduciary Financial Advisors purchased a new stake in shares of CG Oncology in the 2nd quarter worth approximately $28,000. NFSG Corp purchased a new position in CG Oncology during the first quarter valued at approximately $34,000. Comerica Bank increased its holdings in CG Oncology by 100.4% during the fourth quarter. Comerica Bank now owns 1,028 shares of the company’s stock valued at $43,000 after buying an additional 515 shares during the period. Fifth Third Bancorp purchased a new position in CG Oncology during the first quarter valued at approximately $74,000. Finally, KBC Group NV bought a new position in CG Oncology in the first quarter worth approximately $78,000. Institutional investors own 26.56% of the company’s stock.

Insider Transactions at CG Oncology

In other news, Director James Mulay sold 24,165 shares of the firm’s stock in a transaction on Friday, July 10th. The stock was sold at an average price of $75.16, for a total value of $1,816,241.40. Following the completion of the sale, the director owned 24,165 shares of the company’s stock, valued at $1,816,241.40. This trade represents a 50.00% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Leonard E. Post sold 1,000 shares of the business’s stock in a transaction on Friday, August 14th. The stock was sold at an average price of $74.54, for a total value of $74,540.00. Following the transaction, the director owned 1,000 shares in the company, valued at approximately $74,540. This trade represents a 50.00% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 38,129 shares of company stock valued at $2,738,357 in the last quarter. 4.80% of the stock is currently owned by corporate insiders.

CG Oncology Stock Down 5.9%

NASDAQ CGON opened at $74.34 on Friday. CG Oncology, Inc. has a 52 week low of $26.22 and a 52 week high of $80.97. The company has a 50 day moving average price of $73.04 and a 200 day moving average price of $66.46. The firm has a market cap of $6.59 billion, a PE ratio of -27.64 and a beta of 0.23.

CG Oncology (NASDAQ:CGON – Get Free Report) last announced its earnings results on Thursday, August 6th. The company reported ($0.90) earnings per share for the quarter, missing the consensus estimate of ($0.66) by ($0.24). The firm had revenue of $1.16 million during the quarter, compared to analyst estimates of $0.36 million. CG Oncology had a negative net margin of 3,602.68% and a negative return on equity of 25.20%. On average, equities research analysts anticipate that CG Oncology, Inc. will post -3.27 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts have issued reports on CGON shares. Truist Financial increased their target price on CG Oncology from $82.00 to $85.00 and gave the company a “buy” rating in a research report on Friday, August 7th. Royal Bank Of Canada reduced their price target on CG Oncology from $81.00 to $79.00 and set an “outperform” rating for the company in a research report on Friday, August 7th. Wolfe Research initiated coverage on CG Oncology in a research note on Tuesday, May 19th. They set a “peer perform” rating for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of CG Oncology in a research report on Friday, July 17th. Finally, Wall Street Zen downgraded CG Oncology from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 8th. Eleven equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, CG Oncology has an average rating of “Moderate Buy” and a consensus target price of $83.18.

Get Our Latest Analysis on CGON

CG Oncology Company Profile

(Free Report)

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.